Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a promising biopharmaceutical firm with a strong focus on cancer treatments. The company's pipeline includes multiple potential blockbuster drugs, and its upcoming catalysts, such as the initiation of Phase 3 trials for zanzalintinib and topline results from its Phase 3 study of zanzalintinib in combination with Opdivo, have the potential to significantly boost the company's valuation. Additionally, the company's strong cash flow and share repurchase program provide additional support for its stock. However, investors should be aware of the inherent risks associated with drug development and the competitive landscape of the industry, as well as the potential for dilution through future equity offerings.

Bears say

Exelixis is facing potential challenges with their current commercial portfolio as Cabometyx approaches its patent expiry in 2031 and their pipeline drug zanzalintinib displays comparable efficacy, but lacks meaningful statistical significance in certain subsets. Additionally, their early-stage ADC platform is still in the early stages of development and may not provide meaningful returns in the near future. With only two weeks of data missing, it appears Exelixis' stock may have reached its peak and could see a decline in the near term.

Exelixis (EXEL) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Hold based on their latest research and market trends.

According to 12 analysts, Exelixis (EXEL) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.